[8-K] HCW Biologics Inc. Reports Material Event

Rhea-AI Filing Summary

CION Investment Corporation filed a Form 8-K on July 1, 2025 to furnish notice of its upcoming second-quarter 2025 earnings release. Management will publish results before the market opens on Thursday, August 7, 2025, followed by a live conference call at 11:00 a.m. Eastern Time the same day. The disclosure is made under Item 2.02 (Results of Operations and Financial Condition) and is cross-referenced to Item 7.01 (Regulation FD). No quantitative financial information, outlook, or other material developments were provided. Exhibit 99.1 contains the related press release and Exhibit 104 contains the Inline XBRL cover page.

Insights

Financial Analyst

TL;DR: Routine scheduling notice; no new financial data; market impact neutral.

The filing merely informs investors of the date and time for CION’s Q2-25 earnings release and conference call. Because it lacks financial metrics, guidance, or strategic updates, it does not change the investment thesis. Such procedural announcements are standard under Reg FD to ensure equal information access and comply with disclosure obligations. Investors should monitor the August 7 release for performance details, but today’s 8-K should have negligible effect on valuation or trading activity.

0001828673false00018286732025-06-182025-06-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2025

HCW Biologics Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40591	82-5024477
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2929 N. Commerce Parkway
Miramar, Florida				33025
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 954 842-2024

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		HCWB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 Other Events.

As reported in our Current Report on Form 8-K filed on May 15, 2025, HCW Biologics Inc. (the “Company”) entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. (“Armistice”) on May 13, 2025 that included a grant of pre-funded warrants to purchase up to 513,140 shares of the Company’s common stock with par value of $0.0001 per share (“Common Stock”) that may be exercised at any time at an exercise price of $0.0001 per share (the “Pre-Funded Warrants”). As previously reported by the Company, Armistice exercised Pre-Funded Warrants to purchase an aggregate of 459,140 shares of Common Stock. On June 18, 2025, Armistice exercised Pre-Funded Warrants to purchase 54,000 shares of Common Stock. With this exercise, the Pre-Funded Warrants have been fully exercised with none left outstanding.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			HCW BIOLOGICS INC.
Date:	July 1, 2025	By:	/s/ Hing C. Wong
			Hing C. Wong, Founder and Chief Executive Officer

FAQ

When will CION (CION) report its Q2 2025 earnings?

CION plans to release Q2 2025 results on Thursday, August 7, 2025 before market open.

What time is CION’s Q2 2025 earnings conference call?

Management will host the call at 11:00 a.m. Eastern Time on August 7, 2025.

Where can I find the press release for the upcoming earnings announcement?

The press release is attached as Exhibit 99.1 to the Form 8-K filed on July 1, 2025.

Which Form 8-K items were used for this disclosure?

The company furnished information under Item 2.02 and incorporated it into Item 7.01 (Reg FD).

Does this filing include any actual Q2 2025 financial results for CION?

No. The 8-K only announces the reporting schedule; it contains no financial figures for the quarter.